By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


SEARCH JOBS



Segment
Start Up

Collaborations

Dyax  Antibody phage display





Company News
Merrimack (MACK) Release: Updated Data Shows ONIVYDE (irinotecan liposome injection) Combination Regimen Increased One Year Survival By 63% In Patients With Metastatic Pancreatic Cancer 1/20/2016 5:57:48 AM
Merrimack (MACK) To Present Updated Overall Survival Analysis Of Phase 3 NAPOLI-1 Study Of ONIVYDE (irinotecan liposome injection) At The ASCO 2016 Gastrointestinal Cancers Symposium 1/11/2016 6:26:36 AM
Merrimack (MACK) To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/5/2016 10:02:47 AM
Merrimack (MACK) Amends MM-121 Phase 2 Clinical Study In Heregulin-Positive Non-Small Cell Lung Cancer To Support Potential Registration 12/23/2015 6:49:35 AM
Merrimack (MACK) Announces Private Placement Of $175 Million of Senior Secured Notes 12/23/2015 6:47:53 AM
Merrimack (MACK) Announces Presentations At The 2015 San Antonio Breast Cancer Symposium 12/4/2015 9:46:04 AM
Merrimack (MACK) And Baxalta (BXLT) Announce Publication Of The ONIVYDE (irinotecan liposome injection) NAPOLI-1 Study In The Lancet 11/23/2015 6:39:29 AM
Merrimack (MACK) Reports Third Quarter 2015 Financial Results 11/10/2015 8:06:04 AM
Merrimack (MACK) To Present Research On Multiple Programs At The 2015 AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer Therapeutics 11/4/2015 7:20:07 AM
Merrimack (MACK) Announces Timing Of Third Quarter 2015 Investor Conference Call 11/2/2015 7:17:45 AM
12345678910...
//-->